" class="no-js "lang="en-US"> Ilyas Singeç - Medtech Alert
Saturday, April 26, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Ilyas Singeç

Ilyas Singeç

About Ilyas Singeç

Physician-Scientist and inaugural Director of the NCATS Stem Cell Translation Laboratory (SCTL) with expertise in iPS cell research and application.

– Areas of interest: stem cell technologies, disease modeling (e.g. neurodegenerative diseases, pain), pharmaceutical application of iPS cells, and cell therapy.

Related Story

Appointments

 FUJIFILM Cellular Dynamics Announces the Appointment of Dr. Ilyas Singeç as Chief Scientific Officer | Pharmtech Focus

FUJIFILM Cellular Dynamics Announces the Appointment of Dr. Ilyas Singeç as Chief Scientific Officer

September 16 2022

FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem […]